Compare iShares MSCI ACWI ETF (ACWI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Smith & Nephew plc — how do they compare? iShares MSCI ACWI ETF trades at $161.56, while Smith & Nephew plc trades at $29.88 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| ACWI | SNN | |
|---|---|---|
52-Week High | $161.44 | $38.70 |
52-Week Low | $132.04 | $28.73 |
Market Cap | — | $12.54B |
Sector | — | Health |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.64, up 0.34% today, with a bullish technical signal from moving averages and strong trend momentum indicated by the ADX. The ETF benefits from robust global earnings growth and significant institutional interest, as highlighted by recent news of major holdings. A forward P/E of 15.5x suggests reasonable valuation amid the rally.
The outlook remains positive, driven by sustained EPS growth and investor inflows into global equity ETFs, particularly in technology. Key risks include potential overbought conditions signaled by RSI and broader market volatility. Analyst sentiment is bullish, supporting further upside potential.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
